New hypoglycemic drug: Liraglutide promotes insulin secretion and Lose weight

New hypoglycemic drug: Liraglutide promotes insulin secretion and Lose weight.  Liraglutide, a new type of hypoglycemic drug, promotes insulin secretion, protects the kidneys and cardiovascular, and can lose weight.

Diabetes is a high-risk factor for a variety of cardiovascular and cerebrovascular diseases. In addition to high blood sugar, many diabetic patients also have cardiovascular diseases or obesity. Therefore, when people develop hypoglycemic drugs, they hope that hypoglycemic drugs can control blood sugar, reduce weight, and protect the cardiovascular system. Today, the author recommends a new type 2 diabetes medicine: liraglutide, which can not only promote the secretion of insulin by pancreatic islet cells, but also suppress appetite and reduce weight, and it also has a protective effect on the cardiovascular system.

Advantages of the new hypoglycemic drug liraglutide

Liraglutide is a glucagon-like peptide 1 receptor agonist [1], as the name implies, it can stimulate the glucagon-like peptide 1 receptor. Glucagon-like peptide 1 receptors are currently found in pancreatic islet cells, gastrointestinal, brain, lung, kidney, immune cells, hypothalamus and cardiovascular system and other organs and tissues. So it will have a role involving multiple systems:

1) Promote insulin secretion and safely lower blood sugar

Liraglutide can activate receptors on pancreatic β cells to promote insulin release, enhance the sensitivity of peripheral tissues to insulin, and reduce postprandial blood sugar. At the same time, it can also inhibit the release of glucagon from pancreatic α cells to lower blood sugar, and because the action of liraglutide is glucose tolerance, hypoglycemia is unlikely to occur.

2) Protect the kidneys and cardiovascular

A study on the effect of liraglutide on the renal function of patients with microalbuminuria stage diabetic nephropathy was to observe the efficacy and safety of liraglutide in the treatment of microalbuminuria stage (stage Ⅲ) diabetic nephropathy. 86 patients with diabetic nephropathy at the microalbuminuria stage were randomly divided into two groups. The control group was given conventional hypoglycemic treatment, and the observation group was given liraglutide treatment on the basis of the control group. After 6 months of treatment, the two groups were compared with body mass index (BMI) , Fasting blood glucose (FBG), urinary microalbumin excretion rate (UMAER), blood creatinine (SCr) and other indicators, it is concluded that liraglutide can protect the kidneys on the basis of lowering blood sugar, improve renal function and cause low The probability of blood sugar is low.

Liraglutide can reduce vascular endothelial damage induced by oxidized low-density lipoprotein, inhibit the morphological changes of coronary smooth muscle cells and contraction fiber dissociation induced by advanced glycation end products, and reduce arteries caused by hyperglycemia and hyperlipidemia Atherosclerosis, thereby protecting the cardiovascular system.

An international multicenter randomized, double-blind, placebo large-scale clinical study demonstrated that liraglutide can reduce the risk of cardiovascular death by 22% in people with diabetes and high cardiovascular risk. Even some countries’s Food and Drug Administration has approved liraglutide’s cardiovascular indications: it is used to reduce major cardiovascular adverse events (cardiovascular death, non-fatal myocardial infarction or non-fatal myocardial infarction) in adult patients with type 2 diabetes with cardiovascular disease. Fatal stroke) risk [1].

3) Lose weight

Liraglutide can inhibit gastric emptying, reduce appetite, and reduce the accumulation of visceral fat such as liver fat and epicardial fat. Studies have shown that people using liraglutide plus lifestyle intervention can lose more weight than pure lifestyle intervention.

Last year, the National Institute of Health and Care Excellence in the United Kingdom announced in the “Guidelines for the Use of GLP-1RA Liraglutide in the British National Health Service” [3] that the recommended indications for liraglutide are: for adult Obesity treatment for non-diabetic hyperglycemia patients with body mass index (BMI) ≥35kg/m2 and high risk factors for cardiovascular diseases such as hypertension or high cholesterol. Although some countries has not been approved for weight loss, the “Out-of-Instruction Drug List (2020 Edition)” of the Guangdong Pharmaceutical Association has been described [4].

to sum up

In short, liraglutide can bring multiple benefits to diabetic patients, such as blood sugar control, blood lipid regulation, and cardiovascular protection. It is worthy of sugar friends to know and understand. At the same time, the price of this medicine is relatively expensive, about 330 yuan. In the future, the price of this medicine will be more affordable to the people and benefit more sugar friends.

(source:internet, reference only)

Disclaimer of medicaltrend.org